Incidence and prevalence of rheumatoid arthritis in Thailand based on National administrative health data and a comprehensive literature review
- PMID: 40596536
- PMCID: PMC12218984
- DOI: 10.1038/s41598-025-07376-w
Incidence and prevalence of rheumatoid arthritis in Thailand based on National administrative health data and a comprehensive literature review
Abstract
Rheumatoid arthritis (RA) is an inflammatory arthritis that causes economic burden. Epidemiologic data may help to improve economic impact and the healthcare system. The incidence and prevalence of RA vary among the regions while there is no data about the incidence and limited data about the prevalence of RA in Thailand. We aim to estimate the incidence and prevalence of RA in Thailand between 2017 and 2020. The descriptive epidemiologic study was performed using the Information and Communication Technology Center, Ministry of Public Health covering all different healthcare providers during the study period. Demographic data from a primary diagnosis of M05: seropositive rheumatoid arthritis according to ICD 10 and over 18 years of age between 2017 and 2020 were reviewed. The incidence and prevalence of RA were analyzed with their 95% confidence interval (CI) from an overall national perspective and regionally. In 2020, there were 64,849 RA cases in Thailand out of a total population of 65,421,139. The prevalence of RA in 2020 was 99.2 per 100,000 (95% CI 98.2-99.8), with the highest prevalence in the southern region at 135.9 per 100,000 (95% CI 132.2-139.6). Most cases were among women (78.3%), and the highest prevalence was observed in patients aged 60-69 years, at 294.5 per 100,000 (95% CI 290.3-298.6). The incidence of RA increased from 2018 to 2019 but slightly decreased in 2020, reported at 18.6, 18.8, and 18.2 per 100,000 person-years, respectively. Among women, the incidence was 28.6, 28.8, and 27.9 per 100,000 person-years, while in men it was lower, at 8.2, 8.3, and 8.0 per 100,000 person-years from 2018 to 2020. The peak incidence occurred in patients aged 60-69 years, with rates of 58.86, 58.3, and 56.23 per 100,000 person-years from 2018 to 2020. The southern region also had the highest incidence, at 30.4 per 100,000 person-years in 2018, 29.5 in 2019, and 28.1 in 2020. In Thailand, RA was predominantly observed in women of late middle age, with the highest prevalence and incidence occurring in the 60-69 age group. RA was 3.4 times more common in women than in men. The southern region reported the highest prevalence and incidence of RA.
Keywords: Epidemiology; Incidence; Inflammatory arthritis; Prevalence; Rheumatoid arthritis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Short running title: Epidemiologic study of rheumatoid arthritis in Thailand. Disclosures: The authors declare no competing interests to report. Ethics approval: The Human Research Ethics Committee of Khon Kaen University reviewed and approved the study. The study was conducted in accordance with Helsinki Declaration and the Good Clinical Practice Guidelines (HE661176). The Human Research Ethics Committee of Khon Kaen University waived the requirement for informed consent because of the retrospective nature of the study. Participant privacy was protected by anonymized data and kept confidentiality.
Figures


Similar articles
-
Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health.Clin Rheumatol. 2023 Jul;42(7):1767-1774. doi: 10.1007/s10067-023-06550-7. Epub 2023 Mar 10. Clin Rheumatol. 2023. PMID: 36894730 Free PMC article.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Celecoxib for rheumatoid arthritis.Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD012095. doi: 10.1002/14651858.CD012095.pub2. Cochrane Database Syst Rev. 2017. PMID: 28597983 Free PMC article.
References
-
- Fallon, E. A. Prevalence of Diagnosed Arthritis — United States, 2019–2021. MMWR Morb Mortal Wkly Rep [Internet]. 2023 [cited 2024 Nov 10];72. Available from: https://www.cdc.gov/mmwr/volumes/72/wr/mm7241a1.htm - PMC - PubMed
-
- Cross, M. et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis.73 (7), 1316–1322 (2014). - PubMed
-
- Cross, M. et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann. Rheum. Dis.73 (7), 1323–1330 (2014). - PubMed
-
- Safiri, S. et al. Global, regional and National burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis.78 (11), 1463–1471 (2019). - PubMed
-
- Almutairi, K., Nossent, J., Preen, D., Keen, H. & Inderjeeth, C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol. Int.41 (5), 863–877 (2021). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical